Home
HelpMayo Test ID MSCG Collagenofibrotic Glomerulopathy Confirmation, Mass Spectrometry
Necessary Information
Preliminary pathology report, history, and electron microscopy images are required.
Specimen Required
Supplies: Pathology Packaging Kit (T554)
Specimen Type: Formalin-fixed, paraffin-embedded kidney tissue block
Collection Instructions: Do not send fixed tissue slides. Testing can only be done on paraffin-embedded tissue blocks.
Useful For
Aiding in the diagnosis of collagenofibrotic glomerulopathy
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| MLCPC | Microdissection, Laser Capture | No, (Bill Only) | No |
| MSPTC | Mass Spectrometry | No, (Bill Only) | No |
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
CG Confirm, LC MSSpecimen Type
SpecialSpecimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Special | Ambient (preferred) | ||
| Frozen | |||
| Refrigerated | |||
Reject Due To
| Fixed tissue slides Wet/frozen tissue Cytological smears Nonformalin fixed tissue Nonparaffin embedded tissue |
Reject |
Clinical Information
Collagenofibrotic glomerulopathy (CG), also called collagen type III glomerulopathy, is a rare kidney disease characterized by large amounts of atypical type III collagen fibrils in the mesangium and subendothelial space of renal glomeruli. Liquid chromatography tandem mass spectrometry performed on microdissected glomeruli from patients with CG demonstrates a unique proteomic profile. The presence of type III collagen, in the appropriate clinical and pathological context, can be useful to establish a diagnosis of CG.
Interpretation
An interpretation will be provided.
Cautions
No significant cautionary statements
Clinical Reference
1. Chen X, Wan H, Xu W, Zhu J. Collagen type III glomerulopathy: Case report and review of the literature. Clin Nephrol. 2017;1:39-46
2. Dong J, Wei H, Han M, Guan Y, Wu Y, Li H. Collagen type III glomerulopathy: A case report and review of 20 cases. Exp Ther Med. 2015;10(4):1445-1449
3. Kurien AA, Larsen CP, Cossey N. Collagenofibrotic glomerulopathy. Clin Kidney J. 2015;8(5):543-547
4. Cohen AH. Collagen type III glomerulopathies. Adv Chronic Kidney Dis. 2012;19(2):101-106
5. Duggal R, Nada R, Rayat CS, Sakhuja V, Joshi K. Collagenofibrotic glomerulopathy - a review. Clin Kidney J. 2012;5(1):7-12
Method Description
Affected areas are removed from paraffin-embedded tissues by laser microdissection. Protein digestion is performed, followed by liquid chromatography tandem mass spectrometry.(Unpublished Mayo method)
Day(s) Performed
Monday through Friday
Report Available
7 to 15 daysSpecimen Retention Time
Until reportedPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82542
88380
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MSCG | CG Confirm, LC MS | 65757-7 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 615299 | Interpretation | 50595-8 |
| 615300 | Participated in the Interpretation | No LOINC Needed |
| 615301 | Report electronically signed by | 19139-5 |
| 615302 | Material Received | 81178-6 |
| 615303 | Disclaimer | 62364-5 |
| 615304 | Case Number | 80398-1 |
| 617019 | Gross Description | 22634-0 |
| 617020 | Addendum | 35265-8 |
Reference Values
An interpretive report will be provided.